Sherene Loi, MD· @LoiSher · X·· 1 天前评分70
正文 · 机器翻译
#ESMO2026
PostMonarch——改用 Fulvestrant 对比安慰剂联合 Abema-，继续显示出更好的 PFS 和 OS
➡️ 按 ESR1 状态划分的结果令人期待！
#ESMOAmbassadors @OncoAlert
在线发表于 @Annals_Oncology
150 浏览 · 5 赞 · 4 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Sherene Loi, MD · x.com